Helperby Therapeutics-Cadila Pharmaceuticals partnership has World’s First Antibiotic Resistance Breaker in Development
The Helperby Therapeutics-Cadila Pharmaceuticals partnership announced that potentially life-saving treatments are now in development – just six months after signing their agreement.
Helperby Therapeutics, a spin-out of St George’s University of London and one of the few pioneers globally working to overcome antibiotic resistance, has discovered that combining its patented resistance breakers with obsolete antibiotics can produce effective microbial kill rates with significantly lower or no toxicity to the patient.
The partnership is developing a potential treatment against the world’s most deadly superbugs, gram-negative carbapenem-resistant organisms. The last line of defence for patients critically ill with this deadly organism is colistin - an antibiotic with serious side effects and to which resistance is already beginning to emerge.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.